Vicinitas Therapeutics

Executive Summary

Vicinitas Therapeutics is pioneering a novel targeted protein stabilization platform called Deubiquitinase Targeting Chimeras (DUBTACs), which leverages the deubiquitination process to stabilize disease-relevant proteins, offering a new therapeutic modality distinct from traditional protein degradation approaches. The company focuses on oncology and rare diseases, addressing conditions where protein loss or dysfunction drives pathogenesis. Founded in 2020 and headquartered in South San Francisco, Vicinitas has raised $65 million to advance its preclinical pipeline toward candidate selection. The DUBTAC platform has the potential to unlock previously undruggable targets by selectively stabilizing proteins, opening new avenues for therapy. Currently, Vicinitas is advancing multiple preclinical programs targeting oncology and rare disease indications. The company is progressing toward lead candidate nomination and expects to complete IND-enabling studies within the next 12-18 months. With its innovative approach and experienced management team, Vicinitas is well-positioned to attract further partnerships and funding to support clinical development. The key upcoming catalysts include the nomination of a development candidate and initiation of IND-enabling toxicology studies, which will de-risk the platform and pave the way for first-in-human trials.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate nomination for lead oncology program80% success
• Q2 2027Completion of IND-enabling studies for lead program60% success
• H1 2027Series B financing or major pharma partnership70% success